Setmelanotide - Rhythm Pharmaceuticals

Drug Profile

Setmelanotide - Rhythm Pharmaceuticals

Alternative Names: BIM-22493; CAM 4072; RM-493

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Developer Charite - Universitatsmedizin Berlin; Ipsen; Rhythm
  • Class Amides; Antihyperglycaemics; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Obesity
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Phase I Diabetes mellitus

Most Recent Events

  • 12 Mar 2018 Rhythm plans to submit NDA for Obesity in 2019
  • 12 Mar 2018 Rhythm plans to initiate a pivotal phase III trial for Bardet Biedl Syndrome in 2018
  • 10 Jan 2018 Rhythm completes a phase Ia trial (SC) (In volunteers) in Obesity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top